- Home
- AMTB vs URGN Comparison
AMTB vs URGN Comparison
Compare AMTB & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTB
- URGN
- Stock Information
- Founded
- AMTB 1979
- URGN 2004
- Country
- AMTB United States
- URGN United States
- Employees
- AMTB N/A
- URGN N/A
- Industry
- AMTB Major Banks
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- AMTB Finance
- URGN Health Care
- Exchange
- AMTB Nasdaq
- URGN Nasdaq
- Market Cap
- AMTB 837.4M
- URGN 896.3M
- IPO Year
- AMTB N/A
- URGN 2017
- Fundamental
- Price
- AMTB $19.82
- URGN $19.71
- Analyst Decision
- AMTB Buy
- URGN Strong Buy
- Analyst Count
- AMTB 4
- URGN 8
- Target Price
- AMTB $24.00
- URGN $27.75
- AVG Volume (30 Days)
- AMTB 205.6K
- URGN 1.3M
- Earning Date
- AMTB 07-23-2025
- URGN 08-07-2025
- Dividend Yield
- AMTB 1.81%
- URGN N/A
- EPS Growth
- AMTB N/A
- URGN N/A
- EPS
- AMTB 0.09
- URGN N/A
- Revenue
- AMTB $305,477,000.00
- URGN $94,238,000.00
- Revenue This Year
- AMTB $62.62
- URGN $39.80
- Revenue Next Year
- AMTB $6.74
- URGN $108.94
- P/E Ratio
- AMTB $219.95
- URGN N/A
- Revenue Growth
- AMTB N/A
- URGN 10.85
- 52 Week Low
- AMTB $16.21
- URGN $3.42
- 52 Week High
- AMTB $26.24
- URGN $21.02
- Technical
- Relative Strength Index (RSI)
- AMTB 54.72
- URGN 62.57
- Support Level
- AMTB $18.50
- URGN $17.21
- Resistance Level
- AMTB $20.59
- URGN $20.55
- Average True Range (ATR)
- AMTB 0.53
- URGN 1.21
- MACD
- AMTB 0.05
- URGN -0.18
- Stochastic Oscillator
- AMTB 67.23
- URGN 66.92
About AMTB Amerant Bancorp Inc.
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.